Jubilant Pharmova announces Completion of Pharmacovigilance Inspection by the USFDA with No Observations

Jubilant Pharmova Limited announced completion of the United States Food and Drug Administration (USFDA) Post-marketing Adverse Drug Experience (PADE) inspection of Jubilant Cadista Pharmaceuticals Inc, USA, a subsidiary of its wholly owned subsidiary Jubilant Pharma Limited on September 19, 2025. The inspection closed with no observations.

The above inspection concluded with zero observations, reaffirming Jubilant commitment to maintaining the highest standards of quality, safety, and compliance.

Shares of Jubilant Pharmova Limited was last trading in BSE at Rs. 1103.45 as compared to the previous close of Rs. 1114.90. The total number of shares traded during the day was 6641 in over 764 trades.

The stock hit an intraday high of Rs. 1117.40 and intraday low of 1084.05. The net turnover during the day was Rs. 7349230.00.

Source : Equity Bulls

Keywords

JubilantPharmova INE700A01033 USFDA PADEInspection JubilantCadistaPharmaceuticals